Related Experiment Video
Updated: Dec 3, 2025
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
New anti-HER2 agents for brain metastasis: histology-agnostic weapons?
Paolo Tarantino1,2, Aleix Prat3,4, Giuseppe Curigliano5,6
1European Institute of Oncology IRCCS, Milan, Italy.
Abstract:
Besides predicting responsiveness to anti-HER2 agents, HER2 aberrations are associated with a high incidence of central nervous system (CNS) metastasis across several cancer types, including breast, lung, gastric and colorectal cancer. In this setting, several novel anti-HER2 agents with relevant CNS activity are emerging, including tucatinib and trastuzumab deruxtecan. Both agents are already FDA-approved for treating advanced breast cancer, but are also being tested for the treatment of other HER2-driven histologies. The confirmation of their activity in other cancer types may provide histology-agnostic weapons against HER2-driven brain metastasis, possibly improving the prognosis of a wide population of cancer patients.
Insights
HER2 aberrations drive central nervous system (CNS) metastasis in various cancers. Novel anti-HER2 agents like tucatinib show promise for treating HER2-driven brain metastases across histologies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- HER2 aberrations are linked to increased central nervous system (CNS) metastasis in breast, lung, gastric, and colorectal cancers.
- HER2-driven cancers often present challenges due to the blood-brain barrier limiting treatment efficacy.
Discussion:
- Emerging anti-HER2 therapies, including tucatinib and trastuzumab deruxtecan, demonstrate significant CNS activity.
- These agents are approved for advanced breast cancer and are under investigation for other HER2-driven cancers.
- Their potential for histology-agnostic use in HER2-driven brain metastases is a key area of research.
Key Insights:
- HER2 aberrations are a significant risk factor for CNS metastasis.
- Novel anti-HER2 agents possess improved blood-brain barrier penetration and CNS efficacy.
- Tucatinib and trastuzumab deruxtecan represent promising therapeutic options for HER2-positive brain metastases.
Outlook:
- Confirmation of efficacy in diverse HER2-driven histologies could lead to histology-agnostic treatment paradigms.
- These agents may improve outcomes for a broad patient population with HER2-driven brain metastases.
- Further clinical trials are essential to establish the role of these novel agents in CNS metastatic disease.
